

(20463)

Medical Benefit		Effective Date: 01/01/18	Next Review Date: 09/19
Preauthorization	No	Review Dates: 09/10, 09/11, 09/12, 09/13, 09/14, 09/15, 09/16, 09/17, 09/18	

This protocol considers this test or procedure investigational. If the physician feels this service is medically necessary, preauthorization is recommended.

The following protocol contains medical necessity criteria that apply for this service. The criteria are also applicable to services provided in the local Medicare Advantage operating area for those members, unless separate Medicare Advantage criteria are indicated. If the criteria are not met, reimbursement will be denied and the patient cannot be billed. Please note that payment for covered services is subject to eligibility and the limitations noted in the patient's contract at the time the services are rendered.

Populations	Interventions	Comparators	Outcomes
Individuals: <ul style="list-style-type: none"> Who are asymptomatic and at average risk of breast cancer by clinical criteria 	Interventions of interest are: <ul style="list-style-type: none"> Testing for common single nucleotide variants associated with a small increase in the risk of breast cancer 	Comparators of interest are: <ul style="list-style-type: none"> Standard clinical risk predictors 	Relevant outcomes include: <ul style="list-style-type: none"> Test accuracy Test validity Morbid events Quality of Life

DESCRIPTION

A number of single nucleotide variants (SNVs), which are single base-pair variations in the DNA sequence of the genome, have been found to be associated with breast cancer and are common in the population but confer only small increases in risk. Commercially available assays test for a number of SNVs to predict an individual's risk of breast cancer relative to the general population. Some of these incorporate clinical information into risk prediction algorithms. The intent of this type of test is to identify subjects at increased risk who may benefit from more intensive surveillance.

SUMMARY OF EVIDENCE

For individuals who are asymptomatic and at average risk of breast cancer by clinical criteria who receive testing for common SNVs variants associated with a small increase in the risk of breast cancer, the evidence includes observational studies. Relevant outcomes are test accuracy and validity, morbid events, and quality of life. Information about analytic performance (reproducibility) of currently marketed tests is lacking. Clinical genetic tests may improve the predictive accuracy of currently used clinical risk predictors. However, the magnitude of improvement is small, and clinical significance is uncertain. Whether the potential harms of these tests due to false-negative and false-positive results are outweighed by the potential benefit associated with improved risk assessment is unknown. Evaluation of this technology is further complicated by the rapidly increasing numbers of SNVs associated with a small risk of breast cancer. Long-term prospective studies with large sample sizes are needed to determine the clinical validity and utility of SNV-based models for use in predicting breast cancer risk. The discrimination offered by the genetic factors currently known is insufficient to inform clinical practice. The evidence is insufficient to determine the effects of the technology on health outcomes.

POLICY

Testing for one or more single nucleotide variants to predict an individual's risk of breast cancer is considered **investigational**.

The BREVAGen^{plus}® breast cancer risk test is considered **investigational** for all indications, including but not limited to use as a method of estimating individual patient risk for developing breast cancer.

POLICY GUIDELINES**GENETICS NOMENCLATURE UPDATE**

The Human Genome Variation Society nomenclature is used to report information on variants found in DNA and serves as an international standard in DNA diagnostics. It is being implemented for genetic testing medical protocol review updates starting in 2017 (see Table PG1). The Society's nomenclature is recommended by the Human Variome Project, the HUman Genome Organization, and by the Human Genome Variation Society itself.

The American College of Medical Genetics and Genomics and the Association for Molecular Pathology standards and guidelines for interpretation of sequence variants represent expert opinion from both organizations, in addition to the College of American Pathologists. These recommendations primarily apply to genetic tests used in clinical laboratories, including genotyping, single genes, panels, exomes, and genomes. Table PG2 shows the recommended standard terminology—"pathogenic," "likely pathogenic," "uncertain significance," "likely benign," and "benign"—to describe variants identified that cause Mendelian disorders.

Table PG1. Nomenclature to Report on Variants Found in DNA

Previous	Updated	Definition
Mutation	Disease-associated variant	Disease-associated change in the DNA sequence
	Variant	Change in the DNA sequence
	Familial variant	Disease-associated variant identified in a proband for use in subsequent targeted genetic testing in first-degree relatives

Table PG2. ACMG-AMP Standards and Guidelines for Variant Classification

Variant Classification	Definition
Pathogenic	Disease-causing change in the DNA sequence
Likely pathogenic	Likely disease-causing change in the DNA sequence
Variant of uncertain significance	Change in DNA sequence with uncertain effects on disease
Likely benign	Likely benign change in the DNA sequence
Benign	Benign change in the DNA sequence

American College of Medical Genetics and Genomics; AMP: Association for Molecular Pathology.

GENETIC COUNSELING

Experts recommend formal genetic counseling for patients who are at risk for inherited disorders and who wish to undergo genetic testing. Interpreting the results of genetic tests and understanding risk factors can be difficult for some patients; genetic counseling helps individuals understand the impact of genetic testing, including the possible effects the test results could have on the individual or their family members. It should be noted that genetic counseling may alter the utilization of genetic testing substantially and may reduce inappropriate testing; further, genetic counseling should be performed by an individual with experience and expertise in genetic medicine and genetic testing methods.

CLINICAL GENETIC TESTS

BREVAGen^{plus}® is not offered over the Internet or directly to consumers. A physician must order this test. *BRCA*

genetic testing should be used in those from high-risk families (see the Genetic Testing for Hereditary Breast and Ovarian Cancer Syndrome Protocol for details).

MEDICARE ADVANTAGE

For Medicare Advantage testing for one or more single nucleotide polymorphisms (SNPs) for chromosomal abnormalities is considered **not medically necessary**.

BACKGROUND

GENE VARIANTS AND BREAST CANCER RISK

Rare, single-gene variants conferring a high risk of breast cancer have been linked to hereditary breast cancer syndromes. Examples are variants in BRCA1 and BRCA2. These, and a few others, account for less than 25% of inherited breast cancer. Moderate risk alleles, such as variants in the CHEK2 gene, are also relatively rare and apparently explain very little of the genetic risk.

In contrast, several common single SNVs associated with breast cancer have been identified primarily through genome-wide association studies of very large case-control populations. These alleles occur with high frequency in the general population, and the increased breast cancer risk associated with each is very small relative to the general population risk. Some have suggested that these common-risk SNVs could be combined for individualized risk prediction either alone or in combination with traditional predictors; personalized breast cancer screening programs could then vary by starting age and intensity according to risk. Along these lines, the American Cancer Society recommends that women at high risk (> 20% lifetime risk) should undergo breast magnetic resonance imaging and a mammogram every year, and those at moderately increased risk (15%-20% lifetime risk) should talk with their doctors about the benefits and limitations of adding magnetic resonance imaging screening to their yearly mammogram.¹

Clinical Genetic Tests

BREVAGenplus

BREVAGenplus evaluates breast cancer-associated SNVs identified in genome-wide association studies. The first-generation test, BREVAGen, included seven SNVs. In a 2015 report, the test included over 70 susceptibility SNVs.² Risk is calculated by combining individual SNV risks with the Gail model risk. BREVAGenplus has been evaluated for use in African-American, white, and Hispanic patient samples age 35 years and older. BREVAGenplus does not detect known high-risk variants (e.g., in BRCA). According to the BREVAGenplus website, the test is “not applicable to women who are already at high risk of breast cancer including those that have a personal or extensive family history of breast and/or ovarian cancer, LCIS [lobular carcinoma in situ], DCIS [ductal carcinoma in situ], AH [atypical hyperplasia] or have thoracic RT [radiotherapy] under 30y. Any women with these risk factors are already at increased risk of breast cancer and should be screened and followed as such.”³

REGULATORY STATUS

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests (LDTs) must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments (CLIA). BREVAGenplus® (Phenogen Sciences, a subsidiary of Genetic Technologies, Melbourne, Australia) is available under the auspices of CLIA. Laboratories that offer LDTs must be licensed by CLIA for high-

complexity testing. To date, the U.S. Food and Drug Administration has chosen not to require any regulatory review of this test.

Under current regulations, CLIA requires that laboratories demonstrate the analytical validity of the tests they offer. However, there is no requirement for a test to demonstrate clinical validity or clinical utility. Some states (e.g., New York) have chosen to regulate direct-to-consumer laboratories. Because these reviews are not public, the scientific standards applied are unknown.

RELATED PROTOCOL

Genetic Testing for Hereditary Breast and Ovarian Cancer Syndrome

Services that are the subject of a clinical trial do not meet our Technology Assessment Protocol criteria and are considered investigational. *For explanation of experimental and investigational, please refer to the Technology Assessment Protocol.*

It is expected that only appropriate and medically necessary services will be rendered. We reserve the right to conduct prepayment and postpayment reviews to assess the medical appropriateness of the above-referenced procedures. **Some of this protocol may not pertain to the patients you provide care to, as it may relate to products that are not available in your geographic area.**

REFERENCES

We are not responsible for the continuing viability of web site addresses that may be listed in any references below.

1. American Cancer Society. Breast cancer: early detection, diagnosis, and staging topics - Can breast cancer be found early? (Last medical review: 09/25/2014). <http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-detection>. Accessed September 5, 2017.
2. Allman R, Dite GS, Hopper JL, et al. SNPs and breast cancer risk prediction for African American and Hispanic women. *Breast Cancer Res Treat*. Dec 2015;154(3):583-589. PMID 26589314
3. Genetic Technologies. BREVAGenplus®. 2017; <http://brevagenplus.com>. Accessed September 4, 2017.
4. Mealiffe ME, Stokowski RP, Rhees BK, et al. Assessment of clinical validity of a breast cancer risk model combining genetic and clinical information. *J Natl Cancer Inst*. Nov 3 2010;102(21):1618-1627. PMID 20956782
5. Stacey SN, Manolescu A, Sulem P, et al. Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. *Nat Genet*. Jul 2007;39(7):865-869. PMID 17529974
6. Easton DF, Pooley KA, Dunning AM, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. *Nature*. Jun 28 2007;447(7148):1087-1093. PMID 17529967
7. Hunter DJ, Kraft P, Jacobs KB, et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. *Nat Genet*. Jul 2007;39(7):870-874. PMID 17529973
8. Thomas G, Jacobs KB, Kraft P, et al. A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). *Nat Genet*. May 2009;41(5):579-584. PMID 19330030
9. Stacey SN, Manolescu A, Sulem P, et al. Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. *Nat Genet*. Jun 2008;40(6):703-706. PMID 18438407

10. Gold B, Kirchhoff T, Stefanov S, et al. Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. *Proc Natl Acad Sci U S A*. Mar 18 2008;105(11):4340-4345. PMID 18326623
11. Ahmed S, Thomas G, Ghousaini M, et al. Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. *Nat Genet*. May 2009;41(5):585-590. PMID 19330027
12. Zheng W, Long J, Gao YT, et al. Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. *Nat Genet*. Mar 2009;41(3):324-328. PMID 19219042
13. Garcia-Closas M, Hall P, Nevanlinna H, et al. Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. *PLoS Genet*. Apr 2008;4(4):e1000054. PMID 18437204
14. Beeghly-Fadiel A, Shu XO, Lu W, et al. Genetic variation in VEGF family genes and breast cancer risk: a report from the Shanghai Breast Cancer Genetics Study. *Cancer Epidemiol Biomarkers Prev*. Jan 2011;20(1):33-41. PMID 21119072
15. Cai Q, Wen W, Qu S, et al. Replication and functional genomic analyses of the breast cancer susceptibility locus at 6q25.1 generalize its importance in women of Chinese, Japanese, and European ancestry. *Cancer Res*. Feb 15 2011;71(4):1344-1355. PMID 21303983
16. Han W, Woo JH, Yu JH, et al. Common genetic variants associated with breast cancer in Korean women and differential susceptibility according to intrinsic subtype. *Cancer Epidemiol Biomarkers Prev*. May 2011;20(5):793-798. PMID 21415360
17. Jiang Y, Han J, Liu J, et al. Risk of genome-wide association study newly identified genetic variants for breast cancer in Chinese women of Heilongjiang Province. *Breast Cancer Res Treat*. Jul 2011;128(1):251-257. PMID 21197568
18. Mong FY, Kuo YL, Liu CW, et al. Association of gene polymorphisms in prolactin and its receptor with breast cancer risk in Taiwanese women. *Mol Biol Rep*. Oct 2011;38(7):4629-4636. PMID 21125332
19. Mukherjee N, Bhattacharya N, Sinha S, et al. Association of APC and MCC polymorphisms with increased breast cancer risk in an Indian population. *Int J Biol Markers*. Jan-Mar 2011;26(1):43-49. PMID 21279955
20. Ota I, Sakurai A, Toyoda Y, et al. Association between breast cancer risk and the wild-type allele of human ABC transporter ABCC11. *Anticancer Res*. Dec 2010;30(12):5189-5194. PMID 21187511
21. Ren J, Wu X, He W, et al. Lysyl oxidase 473 G>A polymorphism and breast cancer susceptibility in Chinese Han population. *DNA Cell Biol*. Feb 2011;30(2):111-116. PMID 20929399
22. Yu JC, Hsiung CN, Hsu HM, et al. Genetic variation in the genome-wide predicted estrogen response element-related sequences is associated with breast cancer development. *Breast Cancer Res*. Jan 31 2011;13(1):R13. PMID 21281495
23. Ma H, Li H, Jin G, et al. Genetic variants at 14q24.1 and breast cancer susceptibility: a fine-mapping study in Chinese women. *DNA Cell Biol*. Jun 2012;31(6):1114-1120. PMID 22313133
24. Dai J, Hu Z, Jiang Y, et al. Breast cancer risk assessment with five independent genetic variants and two risk factors in Chinese women. *Breast Cancer Res*. Jan 23 2012;14(1):R17. PMID 22269215
25. Long J, Cai Q, Sung H, et al. Genome-wide association study in East Asians identifies novel susceptibility loci for breast cancer. *PLoS Genet*. Feb 2012;8(2):e1002532. PMID 22383897
26. Huo D, Zheng Y, Ogundiran TO, et al. Evaluation of 19 susceptibility loci of breast cancer in women of African ancestry. *Carcinogenesis*. Apr 2012;33(4):835-840. PMID 22357627
27. McCarthy AM, Armstrong K, Handorf E, et al. Incremental impact of breast cancer SNP panel on risk classification in a screening population of white and African American women. *Breast Cancer Res Treat*. Apr 2013;138(3):889-898. PMID 23474973
28. Schoeps A, Rudolph A, Seibold P, et al. Identification of new genetic susceptibility loci for breast cancer through consideration of gene-environment interactions. *Genet Epidemiol*. Jan 2014;38(1):84-93. PMID 24248812
29. Nickels S, Truong T, Hein R, et al. Evidence of gene-environment interactions between common breast cancer susceptibility loci and established environmental risk factors. *PLoS Genet*. 2013;9(3):e1003284. PMID 23544014

30. Pei J, Li F, Wang B. Single nucleotide polymorphism 6q25.1 rs2046210 and increased risk of breast cancer. *Tumour Biol.* Dec 2013;34(6):4073-4079. PMID 23888322
31. Wu X, Xu QQ, Guo L, et al. Quantitative assessment of the association between rs2046210 at 6q25.1 and breast cancer risk. *PLoS One.* 2013;8(6):e65206. PMID 23785413
32. Liu JJ, Liu JL, Zhang X, et al. A meta-analysis of the association of glutathione S-transferase P1 gene polymorphism with the susceptibility of breast cancer. *Mol Biol Rep.* Apr 2013;40(4):3203-3212. PMID 23334471
33. Zheng W, Zhang B, Cai Q, et al. Common genetic determinants of breast-cancer risk in East Asian women: a collaborative study of 23,637 breast cancer cases and 25,579 controls. *Hum Mol Genet.* Jun 15 2013;22(12):2539-2550. PMID 23535825
34. Yao S, Graham K, Shen J, et al. Genetic variants in microRNAs and breast cancer risk in African American and European American women. *Breast Cancer Res Treat.* Oct 2013;141(3):447-459. PMID 24062209
35. Zhou ZC, Wang J, Cai ZH, et al. Association between vitamin D receptor gene Cdx2 polymorphism and breast cancer susceptibility. *Tumour Biol.* Dec 2013;34(6):3437-3441. PMID 23821301
36. Chen QH, Wang QB, Zhang B. Ethnicity modifies the association between functional microRNA polymorphisms and breast cancer risk: a HuGE meta-analysis. *Tumour Biol.* Jan 2014;35(1):529-543. PMID 23982873
37. Xu Q, He CY, Liu JW, et al. Pre-miR-27a rs895819A/G polymorphisms in cancer: a meta-analysis. *PLoS One.* Jun 2013;8(6):e65208. PMID 23762318
38. Zhong S, Chen Z, Xu J, et al. Pre-mir-27a rs895819 polymorphism and cancer risk: a meta-analysis. *Mol Biol Rep.* Apr 2013;40(4):3181-3186. PMID 23266669
39. Fan C, Chen C, Wu D. The association between common genetic variant of microRNA-499 and cancer susceptibility: a meta-analysis. *Mol Biol Rep.* Apr 2013;40(4):3389-3394. PMID 23271127
40. Michailidou K, Hall P, Gonzalez-Neira A, et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. *Nat Genet.* Apr 2013;45(4):353-361. PMID 23535729
41. Siddiq A, Couch FJ, Chen GK, et al. A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. *Hum Mol Genet.* Dec 15 2012;21(24):5373-5384.
42. Garcia-Closas M, Couch FJ, Lindstrom S, et al. Genome-wide association studies identify four ER negative-specific breast cancer risk loci. *Nat Genet.* Apr 2013;45(4):392-398. PMID 23535733
42. Milne RL, Herranz J, Michailidou K, et al. A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the Breast Cancer Association Consortium. *Hum Mol Genet.* Apr 1 2014;23(7):1934-1946. PMID 24242184
43. Joshi AD, Lindstrom S, Husing A, et al. Additive interactions between susceptibility single-nucleotide polymorphisms identified in genome-wide association studies and breast cancer risk factors in the Breast and Prostate Cancer Cohort Consortium. *Am J Epidemiol.* Nov 15 2014;180(10):1018-1027. PMID 25255808
44. Gu C, Zhou L, Yu J. Quantitative assessment of 2q35-rs13387042 polymorphism and hormone receptor status with breast cancer risk. *PLoS One.* Jul 2013;8(7):e66979. PMID 23894282
45. Gong WF, Zhong JH, Xiang BD, et al. Single nucleotide polymorphism 8q24 rs13281615 and risk of breast cancer: meta-analysis of more than 100,000 cases. *PLoS One.* 2013;8(4):e60108. PMID 23565189
46. Milne RL, Burwinkel B, Michailidou K, et al. Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. *Hum Mol Genet.* Nov 15 2014;23(22):6096-6111. PMID 24943594
47. Lin WY, Brock IW, Connley D, et al. Associations of ATR and CHEK1 single nucleotide polymorphisms with breast cancer. *PLoS One.* Jul 2013;8(7):e68578. PMID 23844225
48. Bodelon C, Malone KE, Johnson LG, et al. Common sequence variants in chemokine-related genes and risk of breast cancer in post-menopausal women. *Int J Mol Epidemiol Genet.* Nov 2013;4(4):218-227. PMID 24319537
49. He XF, Wei W, Li SX, et al. Association between the COMT Val158Met polymorphism and breast cancer risk: a meta-analysis of 30,199 cases and 38,922 controls. *Mol Biol Rep.* Jun 2012;39(6):6811-6823. PMID 22297695

50. Dai ZJ, Shao YP, Ma XB, et al. Association of the three common SNPs of cyclooxygenase-2 gene (rs20417, rs689466, and rs5275) with the susceptibility of breast cancer: an updated meta-analysis involving 34,590 subjects. *Dis Markers*. 2014;2014:484729. PMID 25214704
51. Tang L, Xu J, Wei F, et al. Association of STXBP4/COX11 rs6504950 (G>A) polymorphism with breast cancer risk: evidence from 17,960 cases and 22,713 controls. *Arch Med Res*. Jul 2012;43(5):383-388. PMID 22863968
52. He XF, Wei W, Liu ZZ, et al. Association between the CYP1A1 T3801C polymorphism and risk of cancer: evidence from 268 case-control studies. *Gene*. Oct 24 2014;534(2):324-344. PMID 24513335
53. Tian Z, Li YL, Zhao L, et al. Role of CYP1A2 1F polymorphism in cancer risk: evidence from a meta-analysis of 46 case-control studies. *Gene*. Jul 25 2013;524(2):168-174. PMID 23628800
54. Pineda B, Garcia-Perez MA, Cano A, et al. Associations between aromatase CYP19 rs10046 polymorphism and breast cancer risk: from a case-control to a meta-analysis of 20,098 subjects. *PLoS One*. 2013;8(1):e53902. PMID 23342035
55. Agarwal D, Pineda S, Michailidou K, et al. FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium. *Br J Cancer*. Feb 18 2014;110(4):1088-1100. PMID 24548884
56. Yu Z, Liu Q, Huang C, et al. The interleukin 10 -819C/T polymorphism and cancer risk: a HuGE review and meta-analysis of 73 studies including 15,942 cases and 22,336 controls. *OMICS*. Apr 2013;17(4):200-214. PMID 23574339
57. Zhang H, Wang A, Ma H, et al. Association between insulin receptor substrate 1 Gly972Arg polymorphism and cancer risk. *Tumour Biol*. Oct 2013;34(5):2929-2936. PMID 23708959
58. Zheng Q, Ye J, Wu H, et al. Association between mitogen-activated protein kinase kinase 1 polymorphisms and breast cancer susceptibility: a meta-analysis of 20 case-control studies. *PLoS One*. Mar 2014;9(3):e90771. PMID 24595411
59. Gao J, Kang AJ, Lin S, et al. Association between MDM2 rs 2279744 polymorphism and breast cancer susceptibility: a meta-analysis based on 9,788 cases and 11,195 controls. *Ther Clin Risk Manag*. May 2014;10:269-277. PMID 24790452
60. Wang Z, Wang T, Bian J. Association between MDR1 C3435T polymorphism and risk of breast cancer. *Gene*. Dec 10 2013;532(1):94-99. PMID 24070710
61. Zhong S, Xu J, Li W, et al. Methionine synthase A2756G polymorphism and breast cancer risk: an up-to-date meta-analysis. *Gene*. Sep 25 2013;527(2):510-515. PMID 23845785
62. Saadat M. Paraoxonase 1 genetic polymorphisms and susceptibility to breast cancer: a meta-analysis. *Cancer Epidemiol*. Apr 2012;36(2):e101-103. PMID 22133529
63. Qin K, Wu C, Wu X. Two nonsynonymous polymorphisms (F31I and V57I) of the STK15 gene and breast cancer risk: a meta-analysis based on 5966 cases and 7609 controls. *J Int Med Res*. Aug 2013;41(4):956-963. PMID 23803310
64. Chen J, Yuan T, Liu M, et al. Association between TCF7L2 gene polymorphism and cancer risk: a meta-analysis. *PLoS One*. Aug 2013;8(8):e71730. PMID 23951231
65. Perna L, Butterbach K, Haug U, et al. Vitamin D receptor genotype rs731236 (Taq1) and breast cancer prognosis. *Cancer Epidemiol Biomarkers Prev*. Mar 2013;22(3):437-442. PMID 23300018
66. Zhang K, Song L. Association between vitamin D receptor gene polymorphisms and breast cancer risk: a meta-analysis of 39 studies. *PLoS One*. Apr 2014;9(4):e96125. PMID 24769568
67. Li J, Ju Y. Association between the functional polymorphism of vascular endothelial growth factor gene and breast cancer: a meta-analysis. *Iran J Med Sci*. Jan 2015;40(1):2-12. PMID 25649829
68. He Y, Zhang Y, Jin C, et al. Impact of XRCC2 Arg188His polymorphism on cancer susceptibility: a meta-analysis. *PLoS One*. Mar 2014;9(3):e91202. PMID 24621646
69. He XF, Wei W, Su J, et al. Association between the XRCC3 polymorphisms and breast cancer risk: meta-analysis based on case-control studies. *Mol Biol Rep*. May 2012;39(5):5125-5134. PMID 22161248

70. Pharoah PD, Antoniou AC, Easton DF, et al. Polygenes, risk prediction, and targeted prevention of breast cancer. *N Engl J Med*. Jun 26 2008;358(26):2796-2803. PMID 18579814
71. Reeves GK, Travis RC, Green J, et al. Incidence of breast cancer and its subtypes in relation to individual and multiple low-penetrance genetic susceptibility loci. *JAMA*. Jul 28 2010;304(4):426-434. PMID 20664043
72. Sakoda LC, Jorgenson E, Witte JS. Turning of COGS moves forward findings for hormonally mediated cancers. *Nat Genet*. Apr 2013;45(4):345-348. PMID 23535722
73. Hunter DJ, Altshuler D, Rader DJ. From Darwin's finches to canaries in the coal mine--mining the genome for new biology. *N Engl J Med*. Jun 26 2008;358(26):2760-2763. PMID 18579810
74. Dite GS, Mahmoodi M, Bickerstaffe A, et al. Using SNP genotypes to improve the discrimination of a simple breast cancer risk prediction model. *Breast Cancer Res Treat*. Jun 2013;139(3):887-896. PMID 23774992
75. Mavaddat N, Pharoah PD, Michailidou K, et al. Prediction of breast cancer risk based on profiling with common genetic variants. *J Natl Cancer Inst*. May 2015;107(5):dju036. PMID 25855707
76. Zheng W, Wen W, Gao YT, et al. Genetic and clinical predictors for breast cancer risk assessment and stratification among Chinese women. *J Natl Cancer Inst*. Jul 7 2010;102(13):972-981. PMID 20484103
77. Campa D, Kaaks R, Le Marchand L, et al. Interactions between genetic variants and breast cancer risk factors in the Breast and Prostate Cancer Cohort Consortium. *J Natl Cancer Inst*. Aug 17 2011;103(16):1252-1263. PMID 21791674
78. Wacholder S, Hartge P, Prentice R, et al. Performance of common genetic variants in breast-cancer risk models. *N Engl J Med*. Mar 18 2010;362(11):986-993. PMID 20237344
79. Darabi H, Czene K, Zhao W, et al. Breast cancer risk prediction and individualised screening based on common genetic variation and breast density measurement. *Breast Cancer Res*. Feb 7 2012;14(1):R25. PMID 22314178
80. Armstrong K, Handorf EA, Chen J, et al. Breast cancer risk prediction and mammography biopsy decisions: a model-based study. *Am J Prev Med*. Jan 2013;44(1):15-22. PMID 23253645
81. Cuzick J, Brentnall AR, Segal C, et al. Impact of a panel of 88 single nucleotide polymorphisms on the risk of breast cancer in high-risk women: results from two randomized tamoxifen prevention trials. *J Clin Oncol*. Mar 2017;35(7):743-750. PMID 28029312
82. Bloss CS, Schork NJ, Topol EJ. Effect of direct-to-consumer genomewide profiling to assess disease risk. *N Engl J Med*. Feb 10 2011;364(6):524-534. PMID 21226570
83. McCarthy A, Keller B, Kontos D, et al. The use of the Gail model, body mass index and SNPs to predict breast cancer among women with abnormal (BI-RADS 4) mammograms. *Breast Cancer Res*. Jan 8 2015;17(1):1. PMID 25567532
84. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: genetic/familial high-risk assessment: breast and ovarian. Version 2.2017. http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf. Accessed September 5, 2017.
85. National Cancer Institute. Breast cancer risk assessment tool. <http://www.cancer.gov/bcrisktool/>. Accessed September 5, 2017.
86. Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. *Cancer*. Feb 1 1994;73(3):643-651. PMID 8299086
87. Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. *Stat Med*. Apr 15 2004;23(7):1111-1130. PMID 15057881
88. Visvanathan K, Hurley P, Bantug E, et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. *J Clin Oncol*. Aug 10 2013;31(23):2942-2962. PMID 23835710
89. National Government Services, Inc. (Primary Geographic Jurisdiction - Illinois, New York - Entire State, Connecticut, Massachusetts, Maine, New Hampshire, Rhode Island, Vermont, Wisconsin, Minnesota) Local Coverage Determination (LCD): Molecular Pathology Procedures (L35000), Revision Effective Date for services performed on or after 01/01/2018.